TORONTO--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced results of a study comparing the safety and effectiveness of INFUSE® Bone Graft to autogenous bone graft (bone harvested from the patient) when used in maxillary sinus floor augmentation.
